Next Financial Group’s Nektar Therapeutics NKTR Stock Holding History

Next Financial Group’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$0	Hold	1	–	–	﹤0.01%	2928
2021 Q3	$0	Sell	1 -26	-96%	-$6.25K	﹤0.01%	2791
2021 Q2	$7K	Sell	27 -1	-4%	-$277	﹤0.01%	2107
2021 Q1	$8K	Buy	28 +27	+2,700%	+$8.4K	﹤0.01%	1955
2020 Q4	$0	Sell	1 -379	-100%	-$97.9K	﹤0.01%	2389
2020 Q3	$94K	Buy	+380	New	+$120K	0.01%	891
2020 Q2	–	Sell	-381	Closed	-$102K	–	1434
2020 Q1	$102K	Sell	381 -23	-6%	-$7.11K	0.01%	751
2019 Q4	$131K	Buy	404 +144	+55%	+$41.8K	0.01%	857
2019 Q3	$71K	Buy	260 +3	+1%	+$1.1K	0.01%	1026
2019 Q2	$137K	Buy	+257	New	+$129K	0.01%	794
2019 Q1	–	Sell	-8	Closed	-$4K	–	1959
2018 Q4	$4K	Buy	+8	New	+$4.83K	﹤0.01%	1611
2017 Q3	–	Sell	-18	Closed	-$5K	–	1892
2017 Q2	$5K	Hold	18	–	–	﹤0.01%	1549
2017 Q1	$5K	Buy	+18	New	+$4.05K	﹤0.01%	1518

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Next Financial Group's NKTR Position: Q4 2021 in Review

Next Financial Group held its Nektar Therapeutics (NKTR) position steady in Q4 2021 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2928.

Next Financial Group first reported a position in NKTR in Q1 2017 and has held it in 13 quarters since. The position peaked at $137K in Q2 2019. 240 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

Next Financial Group held 1 share of Nektar Therapeutics worth $0 as of Q4 2021.
Next Financial Group left its Nektar Therapeutics share count unchanged in Q4 2021.
Nektar Therapeutics made up ﹤0.01% of Next Financial Group's portfolio in Q4 2021, its #2928 holding.
Next Financial Group first reported a position in Nektar Therapeutics in Q1 2017 and has held it in 13 quarters since.
Next Financial Group's Nektar Therapeutics position peaked at $137K in Q2 2019.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Next Financial Group's 13F filing for Q4 2021, filed 15 Feb 2022.